← All Sanofi filings

Sanofi 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
SNY
Sanofi
20-F: Sanofi Reports Strong 2025 Growth Driven by Dupixent, Strategic M&A
Sanofi's 2025 annual report highlights robust net sales growth, fueled by Dupixent and strategic acquisitions, despite significant R&D setbacks and ongoing generic competition.
NASDAQ
SNY
Sanofi
20-F: Sanofi's 2024 20-F Filing: Key Financials, Strategic Shifts, and Risk Assessment
Sanofi's 2024 20-F filing reveals a year of strategic transformation, marked by strong performance in key areas, significant R&D investments, and ongoing management of legal and regulatory risks.
NASDAQ
SNY
Sanofi
20-F: Sanofi's Annual Report Reveals Key Financial Data, Strategic Collaborations, and Risk Factors for 2023
Sanofi's 2023 annual report highlights financial performance, strategic collaborations, and key risk factors impacting the global healthcare company.